Many Philadelphia communities are at high risk for lung cancer—and at risk of late diagnosis. In 2022, Temple addressed this challenge by launching the Temple Healthy Chest Initiative (THCI), an innovative program partnering with community providers to get more people screened for lung cancer. What’s more, these same chest CT scans may reveal a variety of other conditions. By using enhanced screening as a portal to address multiple health care needs, Temple is serving as a model for hospitals and health systems nationwide in the quest for health equity. Get to Know THCI>

Temple continues to lead treatment innovation for advanced COPD with clinical research on bronchoscopic lung volume reduction (BLVR). Since 2018, we’ve assessed hundreds of candidates for BLVR, 44% of whom underwent this treatment. Of those, 80% reported positive outcomes, especially with regard to quality of life . We are also pioneering other next-generation COPD treatments, including improved humidified nasal high-flow therapy. Temple is the coordinating site for the national HiFlo COPD Trial, a Phase 3 multi-center randomized trial of myAirvo 3 High Flow Nasal Therapy (HFNT) as an outpatient therapy for patients with moderate to severe COPD. Learn About the HiFlo Trial >

Patients throughout the region with malignant pleural mesothelioma have had few options for treatment until now. Our new Mesothelioma and Pleural Disease program at Temple Lung Center and Fox Chase Cancer Center is focused on providing innovative clinical trials and treatment options such as lung-sparing radical pleurectomy to patients with this rare yet fatal disease. Temple is now the only health system in the Philadelphia region with a high-level mesothelioma center of excellence. Meet the Mesothelioma Care Team>

We’re also a regional and national leader in treatment for another under-recognized condition, tracheobronchomalacia (TBM), a weakening of the windpipe which can exacerbate symptoms in 5–10% of patients with other severe respiratory diseases like COPD and chronic bronchitis. The Tracheobronchomalacia Program offers expert diagnosis of TBM along with medical, surgical or interventional treatment to improve patients’ breathing and quality of life. Learn More About the Program>

Temple continues to lead the nation in bringing hope to patients in need of lung transplants. According to 2022 data from the Scientific Registry of Transplant Recipients, Temple had the highest lung transplant volume of any center in the United States. Our highly experienced lung transplant team often performs successful transplants for patients who would be turned down at other institutions. Read About the Program Highlights >